Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new drug application (NDA) for trastuzumab botidotin was accepted by China's National Medical Products Administration, a Tuesday bourse filing said.
The product is indicated for the treatment of adult patients with HER2 positive unresectable or metastatic breast cancer who have received at least one prior anti-HER2 therapy, according to the biopharmaceutical company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。